Results 161 to 170 of about 114,052 (250)

From pathogen to “living drug factory” innovative strategies and clinical translation of bacteria as programmable intelligent vectors for cancer therapy

BMEMat, EarlyView.
Engineered bacteria serve as smart, living therapeutics that target tumors, deliver drugs, and remodel immunosuppressive microenvironments. This review highlights their potential to potentiate immunotherapy, radiotherapy, and chemotherapy, offering a promising paradigm for precise and synergistic cancer treatment. Abstract The dynamic interplay between
Haonan Shen, Weichen Zhang, Gaoli Niu, Li Wang, Ruiyan Li, Yueyue Fan, Feixue Lu, Lingling Xu, Xiaoyuan Ji, Yong Kang   +9 more
wiley   +1 more source

Early Immune Alterations in Adult Patients with Trauma According to Injury Severity: Cell-Death Patterns and Inflammatory Mediator Profiles. [PDF]

J Clin Med
Park SJ, Kim JY, Yun S, Kim SH, Han KS, Park JH, Yoon YH.   +6 more
europepmc   +1 more source

Engineered immunostimulatory H2O2‐producing microreactors driven by yeast as localized living cancer therapeutics

BMEMat, EarlyView.
Engineered yeast microreactors that produce H2O2 within tumors enable selective cancer cell killing while releasing immunostimulatory components, effectively suppressing local tumor growth and activating systemic antitumor immunity, with further efficacy enhanced by anti‐PD‐1 therapy and transarterial embolization.
Wenqian He, Chunjie Wang, Minming Chen, Weihao Yang, Bin Yu, Yuhang Hu, Hengze Ding, Yifan Yan, Zhijuan Yang, Liangzhu Feng   +9 more
wiley   +1 more source

Reconsidering Granulocyte Infusions in Prolonged Neutropenia: A Case Report. [PDF]

Cureus
Murali A, Seela G, Zimmer M, Donthireddy V.   +3 more
europepmc   +1 more source

Lipid droplet profiling during neutrophil differentiation by stimulated Raman scattering microscopy

Biotechnology Progress, EarlyView.
Abstract Lipid droplets (LDs) are dynamic organelles that serve as metabolic hubs and emerging regulators of immune cell fate. Although LDs have been implicated in immune regulation, how LD metabolism is remodeled during neutrophil differentiation and how stage‐specific LD dynamics shape mature neutrophil function remain poorly defined.
Ting‐Jung Sung, Bin Dong, Jingqiao Shen, Yan Tan, Chi Zhang, Xiaoping Bao   +5 more
wiley   +1 more source

Dynamics of severity-associated immune remodeling by granulocytes and macrophages in acute lung injury. [PDF]

iScience
Zeng W, Wang C, Cao C, Nie C, Fan Y, Zhang Y, He Z.   +6 more
europepmc   +1 more source

Surgical management of persistent gingival recession after sepsis‐associated gingival necrosis in a patient with systemic lupus erythematosus: A case report

Clinical Advances in Periodontics, EarlyView.
Abstract Background Sepsis‐associated gingival necrosis is an uncommon oral manifestation that may result in extensive gingival recession after the resolution of the acute phase. Methods This report presents the 2‐year follow‐up of periodontal management in a 38‐year‐old woman with systemic lupus erythematosus, who developed septic shock accompanied by
Risako Mikami, Koji Mizutani, Ruriko Mizuno, Yuji Kabasawa, Koichiro Matsuo   +4 more
wiley   +1 more source

Polarized hyperspectral and polarized light microscopic imaging for enhanced visualization of white blood cells. [PDF]

J Biomed Opt
Zhou X, Mubarak HK, Ma L, Medina EA, Brimhall BB, Whitted M, Palsgrove D, Shrestha M, Fei B.   +8 more
europepmc   +1 more source

Removal of activated neutrophils by a polymyxin B-immobilized fiber (PMX) column. [PDF]

Int J Artif Organs
Miyamoto Y, Suzuki A, Otsuka H, Kobayashi R, Sekiya Y, Koga Y, Meguro H, Ida N, Miyata M.   +8 more
europepmc   +1 more source

Intravenous Lipopolysaccharide Challenge in Healthy Participants Reveals Pharmacodynamic Markers in Blood and Bone Marrow for Early‐Phase Oncology Drug Development

Clinical Pharmacology &Therapeutics, EarlyView.
Demonstrating pharmacological effects in early‐phase oncology clinical trials remains challenging, largely due to the lack of robust pharmacodynamic markers. Lipopolysaccharide (LPS) is used as an immune challenge agent in healthy participants to study drugs for autoimmune conditions.
Igor Radanović, Ingrid Tomljanović, Wieke H. Grievink, Diana R. Pereira, Michelle Osse, Peter van Balen, Maria J. Juachon, Marieke L. de Kam, Lisa Pagan, Manon A.A. Jansen, Matthijs Moerland, Jacobus J. Bosch   +11 more
wiley   +1 more source